{
    "clinical_study": {
        "@rank": "87195", 
        "acronym": "LIPO-102-CL-11", 
        "arm_group": [
            {
                "arm_group_label": "LIPO-102, Low", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "LIPO-102, Mid", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "LIPO-102, High", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "LIPO-102; Placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "salmeterol xinafoate", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Dose ranging study"
        }, 
        "brief_title": "Dose-ranging Study", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Abdominal Contour Defects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 45 years of age inclusive\n\n          -  abdominal contour defect\n\n          -  BMI <25 kg/msq\n\n          -  Stable diet and exercise and body weight\n\n        Exclusion Criteria:\n\n          -  Prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc)\n\n          -  Known hypersensitivity to study drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712451", 
            "org_study_id": "LIPO-102-CL-11"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LIPO-102, Low", 
                    "LIPO-102, Mid", 
                    "LIPO-102, High"
                ], 
                "description": "LIPO-102", 
                "intervention_name": "salmeterol xinafoate, fluticasone propionate", 
                "intervention_type": "Drug", 
                "other_name": "LIPO-102"
            }, 
            {
                "arm_group_label": "LIPO-102; Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "salmeterol xinafoate", 
                "description": "Salmeterol", 
                "intervention_name": "salmeterol xinafoate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Salmeterol", 
                "Albuterol", 
                "Fluticasone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "adiposity", 
        "lastchanged_date": "October 23, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plano", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects", 
        "overall_official": {
            "affiliation": "Lithera, Inc", 
            "last_name": "Murray Maytom", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "8 weeks treatment"
            }, 
            {
                "description": "abdominal circumference", 
                "measure": "Change in abdominal circumference", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 9 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712451"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in global clinician scale score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 9 weeks"
            }, 
            {
                "measure": "Change in global patient scale score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 9 weeks"
            }, 
            {
                "measure": "Change in Photonumeric scale score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 9 weeks"
            }, 
            {
                "measure": "Change in Patient Reported Outcome Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 9 weeks"
            }
        ], 
        "source": "Lithera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lithera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}